Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05560659
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Overview
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
Sponsor
Peter MacCallum Cancer Centre
Phase
Phase 2
Contacts
Gaurav Sharma (CONTACT)
gaurav.sharma@petermac.org
+61 3 8559 6830
Dr Aravind S. Ravi Kumar (PRINCIPAL_INVESTIGATOR)
A/Prof. Shankar Siva (PRINCIPAL_INVESTIGATOR)
Annette VanDerHeyden (CONTACT)
annette.vanderheyden@petermac.org
+61488048792
ClinicalTrials.gov
NCT05560659Drug / Compound
PSMA-617
Isotope(s):
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
- PSMA
Ligand Class: Small Molecules
Chelator: DOTA
Eligibility
Inclusion
- Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula)
- Haemoglobin ≥100 g/L
- Platelet count \>150x 109/L
- Adequate haematological function as defined by:
- Assessed as suitable for SABR by a radiation oncologist
- Prior definitive treatment of the primary with either curative intent radiotherapy and/or surgery
- Patients must agree to use an adequate method of contraception
- Patient has 1-5 sites of nodal or bony metastases on 68Ga-PSMA or 18F-DCFPyL PET/CT
- Histologically confirmed prostate adenocarcinoma w
- Absolute neutrophil count (ANC) ≥1.5 x 109/L
- Have a performance status of 0-1 on the ECOG Performance Scale
Exclusion
- Prior systemic therapy for metastatic prostate cancer. Prior ADT is allowed but ADT within 6 months of screening for the study is not allowed. If patients have received prior ADT, serum testosterone levels must be above the lower limit of normal
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
- Symptomatic cord compression, or clinical or imaging findings concerning for impending cord compression
- Any visceral (AJCCC M1c) metastases
Share your feedback
Help us improve your experience